ALHC
Alignment Healthcare, Inc. NASDAQ Listed Mar 26, 2021$18.25
Mkt Cap $3.8B
52w Low $11.62
54.1% of range
52w High $23.87
50d MA $19.33
200d MA $18.26
P/E (TTM)
-5475.7x
EV/EBITDA
81.1x
P/B
22.4x
Debt/Equity
1.9x
ROE
-0.4%
P/FCF
34.6x
RSI (14)
—
ATR (14)
—
Beta
1.20
50d MA
$19.33
200d MA
$18.26
Avg Volume
3.1M
Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.
1100 West Town and Country Road · Orange, CA 92868 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 0.01 | 0.05 | +400.0% | 22.54 | -6.3% | -10.1% | -14.6% | -18.8% | -19.5% | -19.0% | — |
| Feb 26, 2026 | AMC | -0.15 | -0.05 | +66.7% | 20.42 | -7.7% | -5.9% | -3.8% | -9.6% | -7.5% | -9.1% | — |
| Oct 30, 2025 | AMC | -0.01 | 0.02 | +300.0% | 17.12 | +8.2% | -1.5% | -1.6% | -0.2% | -0.4% | -3.7% | — |
| Jul 30, 2025 | AMC | -0.07 | 0.07 | +200.0% | 13.00 | +15.4% | +6.0% | -0.2% | +5.1% | +3.2% | +5.5% | — |
| May 1, 2025 | AMC | -0.12 | -0.05 | +58.3% | 16.77 | +1.7% | -7.4% | -7.7% | -6.3% | -7.5% | -8.1% | — |
| Feb 27, 2025 | AMC | -0.18 | -0.16 | +11.1% | 13.47 | +11.8% | +16.5% | +15.2% | +16.9% | +17.4% | +13.2% | — |
| Oct 29, 2024 | AMC | -0.14 | -0.14 | +0.0% | 11.71 | +0.0% | +0.2% | +5.9% | +10.6% | +13.5% | +13.4% | — |
| Aug 1, 2024 | AMC | -0.14 | -0.13 | +7.1% | 8.62 | +3.8% | +3.7% | +2.4% | +6.4% | +1.5% | -2.3% | — |
| May 2, 2024 | AMC | -0.24 | -0.25 | -4.2% | 5.26 | +8.7% | +26.0% | +28.9% | +30.6% | +28.9% | +31.4% | — |
| Feb 27, 2024 | AMC | -0.22 | -0.25 | -13.6% | 6.92 | -5.3% | -18.2% | -13.3% | -18.5% | -22.0% | -21.0% | — |
| Nov 2, 2023 | AMC | -0.19 | -0.19 | +0.0% | 6.35 | +6.1% | -5.2% | -8.0% | -2.7% | -1.6% | -6.9% | — |
| Aug 3, 2023 | AMC | -0.21 | -0.15 | +28.6% | 5.78 | +14.5% | +11.6% | +12.6% | +14.7% | +14.9% | +13.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | UBS | Maintains | Neutral → Neutral | — | $22.54 | $21.12 | -6.3% | -10.1% | -14.6% | -18.8% | -19.5% | -19.0% |
| May 1 | Barclays | Maintains | Equal Weight → Equal Weight | — | $22.54 | $21.12 | -6.3% | -10.1% | -14.6% | -18.8% | -19.5% | -19.0% |
| Feb 5 | JP Morgan | Maintains | Overweight → Overweight | — | $21.33 | $21.53 | +0.9% | -0.8% | +2.0% | -2.7% | -3.3% | -4.4% |
| Jan 16 | TD Cowen | Maintains | Buy → Buy | — | $22.50 | $22.48 | -0.1% | +0.0% | +1.1% | +3.6% | +4.9% | +5.8% |
| Jan 14 | UBS | Maintains | Neutral → Neutral | — | $20.92 | $20.99 | +0.3% | +4.0% | +7.6% | +7.6% | +8.7% | +11.4% |
| Jan 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.00 | $21.45 | +2.1% | +1.4% | -0.3% | -0.2% | -1.0% | +1.3% |
| Dec 17 | JP Morgan | Maintains | Overweight → Overweight | — | $20.03 | $20.07 | +0.2% | +2.6% | +1.9% | +1.9% | +0.8% | -2.5% |
| Nov 24 | JP Morgan | Upgrade | Neutral → Overweight | — | $16.70 | $17.38 | +4.1% | +5.5% | +14.6% | +15.1% | +15.0% | +14.3% |
| Nov 5 | JP Morgan | Maintains | Neutral → Neutral | — | $17.09 | $16.96 | -0.8% | -0.2% | -3.5% | -4.4% | -4.2% | -3.6% |
| Nov 3 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.86 | $17.00 | +0.8% | -0.1% | +1.4% | +1.2% | -2.2% | -3.1% |
| Oct 31 | UBS | Maintains | Neutral → Neutral | — | $17.12 | $18.53 | +8.2% | -1.5% | -1.6% | -0.2% | -0.4% | -3.7% |
| Aug 25 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $15.84 | $16.23 | +2.5% | -1.6% | -1.0% | +1.9% | +3.0% | +3.3% |
| Jul 31 | Barclays | Upgrade | Underweight → Equal Weight | — | $13.00 | $15.00 | +15.4% | +6.0% | -0.2% | +5.1% | +3.2% | +5.5% |
| May 2 | UBS | Maintains | Neutral → Neutral | — | $16.77 | $17.05 | +1.7% | -7.4% | -7.7% | -6.3% | -7.5% | -8.1% |
| Apr 15 | Baird | Maintains | Outperform → Outperform | — | $19.13 | $19.52 | +2.0% | +1.6% | +1.8% | -4.7% | -8.5% | -5.1% |
| Apr 8 | Stifel | Maintains | Buy → Buy | — | $17.82 | $19.73 | +10.7% | +6.3% | +4.0% | +11.0% | +10.8% | +7.4% |
| Mar 6 | JP Morgan | Maintains | Neutral → Neutral | — | $15.81 | $15.65 | -1.0% | -3.5% | -5.8% | -5.0% | -2.5% | -0.6% |
| Mar 4 | BofA Securities | Maintains | Buy → Buy | — | $15.52 | $15.53 | +0.1% | +1.5% | +1.9% | -1.7% | -4.1% | -3.2% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.52 | $15.53 | +0.1% | +1.5% | +1.9% | -1.7% | -4.1% | -3.2% |
| Feb 28 | Stifel | Maintains | Buy → Buy | — | $13.47 | $15.06 | +11.8% | +16.5% | +15.2% | +16.9% | +17.4% | +13.2% |
| Feb 28 | Barclays | Maintains | Underweight → Underweight | — | $13.47 | $15.06 | +11.8% | +16.5% | +15.2% | +16.9% | +17.4% | +13.2% |
| Feb 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $13.18 | $13.36 | +1.4% | +3.4% | +1.6% | -0.2% | +2.2% | +19.0% |
| Jan 14 | Stifel | Maintains | Buy → Buy | — | $13.50 | $13.78 | +2.1% | +0.1% | +3.0% | +7.8% | +8.0% | +7.9% |
| Jan 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $11.25 | $11.32 | +0.6% | +2.8% | +4.0% | +0.6% | +4.3% | +6.3% |
| Dec 3 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $12.84 | $13.29 | +3.5% | -2.3% | -2.5% | -5.0% | -11.3% | -11.0% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $11.73 | $11.70 | -0.3% | +5.7% | +10.4% | +13.3% | +13.2% | +20.6% |
| Oct 30 | UBS | Maintains | Neutral → Neutral | — | $11.71 | $11.71 | +0.0% | +0.2% | +5.9% | +10.6% | +13.5% | +13.4% |
| Oct 30 | Barclays | Maintains | Underweight → Underweight | — | $11.71 | $11.71 | +0.0% | +0.2% | +5.9% | +10.6% | +13.5% | +13.4% |
| Aug 14 | Baird | Maintains | Outperform → Outperform | — | $8.49 | $8.78 | +3.4% | +2.1% | +1.2% | +2.5% | +1.2% | +0.0% |
| Aug 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.83 | $9.09 | +2.9% | +3.9% | -0.9% | -4.6% | -2.4% | -6.5% |
| Aug 6 | TD Cowen | Maintains | Buy → Buy | — | $8.83 | $9.09 | +2.9% | +3.9% | -0.9% | -4.6% | -2.4% | -6.5% |
| Aug 5 | Barclays | Maintains | Underweight → Underweight | — | $8.94 | $8.50 | -4.9% | -1.2% | +2.6% | -2.1% | -5.8% | -3.6% |
| Jul 26 | Stifel | Maintains | Buy → Buy | — | $9.36 | $9.80 | +4.7% | -4.6% | -8.5% | -6.4% | -6.6% | -7.9% |
| May 8 | Piper Sandler | Upgrade | Neutral → Overweight | — | $6.87 | $7.27 | +5.8% | -1.3% | +0.6% | -0.6% | +0.7% | +1.9% |
| May 3 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $5.26 | $5.72 | +8.7% | +26.0% | +28.9% | +30.6% | +28.9% | +31.4% |
| Apr 23 | Stifel | Maintains | Buy → Buy | — | $5.01 | $5.00 | -0.2% | +3.4% | +3.4% | +3.0% | +4.0% | +1.4% |
| Mar 6 | Piper Sandler | Downgrade | Overweight → Neutral | — | $5.47 | $5.18 | -5.3% | -1.8% | -1.5% | -1.5% | -3.1% | -7.5% |
| Feb 28 | UBS | Maintains | Neutral → Neutral | — | $6.92 | $6.55 | -5.3% | -18.2% | -13.3% | -18.5% | -22.0% | -21.0% |
| Jan 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $9.00 | $8.99 | -0.1% | -1.9% | -5.4% | -8.2% | -13.0% | -18.4% |
| Jan 9 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $9.00 | $8.99 | -0.1% | -1.9% | -5.4% | -8.2% | -13.0% | -18.4% |
| Dec 21 | UBS | Maintains | Neutral → Neutral | — | $8.06 | $8.21 | +1.9% | +8.4% | +7.3% | +7.9% | +8.1% | +8.4% |
| Nov 2 | BofA Securities | Downgrade | Buy → Neutral | — | $6.66 | $6.50 | -2.4% | -4.7% | -9.6% | -12.3% | -7.2% | -6.2% |
| Oct 16 | Raymond James | Upgrade | Outperform → Strong Buy | — | $6.62 | $7.61 | +15.0% | +17.2% | +14.7% | +11.9% | +8.9% | +7.3% |
| Aug 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.01 | $5.98 | -0.5% | +1.2% | -2.8% | -4.3% | -3.7% | -5.7% |
| Jul 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.19 | $5.27 | +1.5% | +3.1% | +4.2% | +5.8% | +8.5% | +11.9% |
| Jul 13 | UBS | Maintains | Neutral → Neutral | — | $5.32 | $5.30 | -0.4% | -2.4% | +0.6% | +1.7% | +3.2% | +5.8% |
| Jul 7 | JP Morgan | Maintains | Neutral → Neutral | — | $5.56 | $5.51 | -0.9% | +1.3% | +0.2% | +4.0% | -4.3% | -6.7% |
| May 1 | Raymond James | Upgrade | Market Perform → Outperform | — | $6.29 | $6.71 | +6.7% | +8.9% | +7.8% | +5.9% | +11.3% | +9.5% |
| Apr 19 | Goldman Sachs | Maintains | Buy → Buy | — | $5.95 | $5.95 | +0.0% | -11.6% | -13.9% | -10.6% | -10.1% | -8.7% |
| Mar 3 | Goldman Sachs | Maintains | Buy → Buy | — | $7.40 | $7.40 | +0.0% | +2.7% | -2.6% | -6.8% | -7.0% | -12.2% |
No insider trades available.
8-K
Alignment Healthcare, Inc. -- 8-K Filing
Alignment Healthcare (ALHC) exceeded expectations with 33.3% revenue growth to $1.24 billion and 30.9% Medicare Advantage membership growth, raising full-year guidance across all metrics.
Apr 30
8-K
Alignment Healthcare, Inc. -- 8-K Filing
Alignment Healthcare completed a securities offering with legal opinions filed, indicating the company proceeded with a planned equity issuance under SEC registration.
Mar 4
8-K
Alignment Healthcare, Inc. -- 8-K Filing
Alignment Healthcare reported strong fourth quarter and full-year 2025 Medicare Advantage results, with CEO John Kao highlighting successful operational execution in the growing senior health insurance market.
Feb 26
Data updated apr 24, 2026 5:16pm
· Source: massive.com